Therapeutic area intelligence for Friedreich's Ataxia with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Larimar Therapeutics →

Assets

Larimar →

Recent signals(1)

ClinicalJuly 12, 2026

Larimar Therapeutics Evaluates Nomlabofusp in Pediatric Friedreich's Ataxia Trial

Larimar Therapeutics is conducting a clinical trial to assess the safety and tolerability of nomlabofusp in adolescents and children with Friedreich's ataxia.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.